TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
CAMBRIDGE, Mass., Aug. 30, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in the following conferences in September:
- Citi’s 12th Annual Biotech Conference (panel discussion) on Wednesday, September 6, 2017 at 1:00 p.m. ET in Boston;
- Morgan Stanley’s 15th Annual Global Healthcare Conference (fireside chat) on Monday, September 11, 2017 at 4:15 p.m. ET in New York City;
- Cantor Fitzgerald’s 3rd Annual Healthcare Conference (presentation) on Tuesday, September 26, 2017 at 3:25 p.m. ET in New York City; and,
- Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (fireside chat) on Wednesday, September 27, 2017 at 8:30 a.m. ET in New York City.
Replays of the webcasts will be available in the investor section of the company’s website at http://www.epizyme.com for 60 days following the call and presentation.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company's proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Contacts: Cheya Pope, Epizyme, Inc. [email protected] 617-229-7561 Monique Allaire, THRUST IR [email protected] (617) 895-9511
